Recro Pharma Inc (NASDAQ:REPH) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 652,600 shares, a decrease of 8.4% from the June 30th total of 712,300 shares. Based on an average trading volume of 221,700 shares, the short-interest ratio is presently 2.9 days. Approximately 3.7% of the shares of the stock are short sold.
REPH stock traded down $0.40 during midday trading on Thursday, reaching $10.75. 163,500 shares of the company traded hands, compared to its average volume of 301,603. Recro Pharma has a 52-week low of $5.49 and a 52-week high of $11.85. The business has a 50 day moving average of $10.11 and a 200-day moving average of $9.10. The firm has a market capitalization of $246.48 million, a price-to-earnings ratio of -4.32 and a beta of -0.27.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.29. Recro Pharma had a negative return on equity of 472.52% and a negative net margin of 64.26%. The business had revenue of $31.26 million for the quarter, compared to the consensus estimate of $24.06 million. As a group, equities research analysts forecast that Recro Pharma will post -0.35 EPS for the current year.
A number of brokerages recently commented on REPH. ValuEngine raised Recro Pharma from a “hold” rating to a “buy” rating in a research note on Friday, May 24th. BidaskClub raised Recro Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday. Oppenheimer set a $20.00 price target on Recro Pharma and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Zacks Investment Research raised Recro Pharma from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Thursday. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $12.70.
In other Recro Pharma news, Director Arnaud Ajdler acquired 40,000 shares of the company’s stock in a transaction dated Friday, May 17th. The stock was purchased at an average price of $9.00 per share, with a total value of $360,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 20.10% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of REPH. Engine Capital Management LP boosted its holdings in Recro Pharma by 3.8% in the 2nd quarter. Engine Capital Management LP now owns 1,104,546 shares of the specialty pharmaceutical company’s stock worth $11,233,000 after buying an additional 40,000 shares during the last quarter. Voloridge Investment Management LLC acquired a new stake in Recro Pharma in the 2nd quarter worth about $152,000. Nuveen Asset Management LLC acquired a new stake in Recro Pharma in the 2nd quarter worth about $3,455,000. Morgan Stanley boosted its holdings in Recro Pharma by 1,287.5% in the 2nd quarter. Morgan Stanley now owns 88,135 shares of the specialty pharmaceutical company’s stock worth $896,000 after buying an additional 81,783 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new stake in Recro Pharma in the 2nd quarter worth about $109,000. Hedge funds and other institutional investors own 57.58% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More: When can a hold rating present a buying opportunity?
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.